Gene Symbol	Gene-Disease Validity	HGNC ID	MONDO Disease Name	MONDO ID	MOI	Gene-Disease Validity	Reportable as SF	Gene MIM	Disease/Phentyope	Disorder MIM	Phenotype Category	Inheritance	SF List Version	Variants to report	Reporting Guidance Comment	Механизм	Вывод	Criteria Specifications	Criteria Specification Registry	HI Score	TS Score	PVS1	PS1	PS2	PS3	PS4	PM1	PM2	PM3	PM4	PM5	PM6	PP1	PP2	PP3	PP4	PP5	BA1	BS1	BS2	BS3	BS4	BP1	BP2	BP3	BP4	BP5	BP6	BP7
ABCD1	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_815e0f84-b530-4fd2-81a9-02e02bf352ee-2020-12-18T050000.000Z?page=1&size=25&search=	HGNC:61	adrenoleukodystrophy	MONDO:0018544	XL	Definitive	Yes	300371	X-linked adrenoleukodystrophy Adrenoleukodystrophy Adrenomyeloneuropathy, adult	300100	Metabolic	XL	3,3	All hemi or homozygous P and LP or 2 het. P/LP variants	Hemizygous P/LP variants in males are reportable, as are biallelic P/LP variants in females. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene). Single heterozygous P/LP variants in females are not reportable as SFs. 	loss of function	Lof и missens, много CNV	Нет		3	0																												
ACTA2	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_2f4fb1fe-4b82-481d-a81d-398eea46acc5-2025-01-24T170000.000Z?page=1&size=25&search=	HGNC:130	familial thoracic aortic aneurysm and aortic dissection	MONDO:0019625	AD	Definitive	Yes	102620	Familial thoracic aortic aneurysm Aortic aneurysm, familial thoracic 6	611788	Cardiovascular	AD	1	All P and LP		dominant negative	missens	Нет		1	0																												
ACTC1	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_2f62793b-0015-46eb-bb51-bddbae25ba0d-2021-06-23T201616.296Z?page=1&size=25&search=	HGNC:143	hypertrophic cardiomyopathy	MONDO:0005045	AD	Definitive	Yes	102540	Hypertrophic cardiomyopathy Cardiomyopathy, hypertrophic, 11	612098	Cardiovascular	AD	1	All P and LP		unknown	missens	Есть		1	0																												
ACTC1	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_3e9b4048-3003-4180-b891-fcf10d25a814-2025-04-25T040000.000Z?page=1&size=25&search=	HGNC:143	dilated cardiomyopathy	MONDO:0005021	AD	Moderate	Yes	102540	Cardiomyopathy, dilated, 1R Left ventricular noncompaction 4	613424	Cardiovascular	AD		All P and LP		unknown	missens	Нет		1	0																												
ACTC1	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_748d4255-ef43-4b42-b9f1-1cdbc50de763-2019-03-15T160000.000Z	HGNC:143	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	No Known Disease Relationship	NA	102540										Нет		1	0																												
ACVRL1	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_fbbb72c5-84a0-4096-8d49-6df506cfee0e-2022-12-05T170000.000Z?page=1&size=25&search=	HGNC:175	telangiectasia, hereditary hemorrhagic, type 2	MONDO:0010880	AD	Definitive	Yes	601284	Hereditary hemorrhagic telangiectasia Telangiectasia, hereditary hemorrhagic, type 2	600376	Other	AD	3	All P and LP		haploinsufficiency	разные, есть очень подробные спецификации	Есть		3	0																												
APC	https://search.clinicalgenome.org/kb/conditions/MONDO:0017790	HGNC:583	gastric adenocarcinoma and proximal polyposis of the stomach	MONDO:0017790	AD	Definitive	No	611731									promoter variants	Нет																															
APC	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_cdf062b6-6abf-49f6-a2dc-43b0e535f1b6-2022-06-20T170000.000Z?page=1&size=25&search=	HGNC:583	classic or attenuated familial adenomatous polyposis	MONDO:0021057	AD	Definitive	Yes	611731	Familial adenomatous polyposis Adenomatous polyposis coli Gardner syndrome Adenoma, periampullary, somatic Brain tumor-polyposis syndrome 2	175100	Cancer	AD	1	All P and LP	P/LP variants associated with both classic and attenuated FAP are recommended for return as SFs. At this time, P/LP variants associated with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) are not recommended for return as SFs as the actionability for this phenotype may be different than for FAP and has not yet been evaluated by the ACMG SF committee. In addition, GAPPS is caused by P/LP promoter variants which would only be detectable by genome, not exome sequencing (https://pubmed.ncbi.nlm.nih.gov/39039610/)	loss of function	не promoter variants frame в основном missens почти не описаны	Есть		3	0																												
APOB	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_1c26b83b-409e-47c7-9c53-6ca79472d6fc-2018-11-14T180000.000Z?page=1&size=25&search=	HGNC:603	hypercholesterolemia, autosomal dominant, type B	MONDO:0007751	AD	Definitive	Yes	107730	Familial hypercholesterolemia Hypercholesterolemia, familial, 2	144010	Cardiovascular	AD	1	All P and LP	Pathogenic missense variants in the LDL-receptor binding domain of apoB impair binding of LDL to the LDL receptor, causing hypercholesterolemia and premature coronary artery disease, the primary features of FH. In contrast, pathogenic variants resulting in reduced secretion of APOB (mainly nonsense and frameshift variants) cause familial hypobetalipoproteinemia, which is characterized by hypocholesterolemia and resistance to atherosclerosis. Therefore, only P/LP missense variants with documented association with hypercholesterolemia are reportable as SFs.	mainly heterozygous missense variants resulting in defective apo B100 on LDL particles that fails to bind to LDLR	missens только	Нет		3	0																												
APOB	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_e7382aae-83d5-4a23-b1fe-e3d6acea8584-2020-02-26T170000.000Z?page=1&size=25&search=	HGNC:603	familial hypobetalipoproteinemia 1	MONDO:0014252	SD	Definitive	No	107730	Hypobetalipoproteinemia	615558		AR					nonsense and frameshift variants	Нет		3	0																												
ATP7B	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_f0ac0a41-d7d5-4377-a622-1ee9bc4ed9f3-2019-03-27T160000.000Z?page=1&size=25&search=	HGNC:870	Wilson disease	MONDO:0010200	AR	Definitive	Yes	606882	Wilson disease	277900	Other	AR	2	P and LP (2 variants)	ATP7B is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return if the variants do not have prior evidence of existing in cis (on the same copy of the gene).	loss of function	любые	Нет		30	0																												
BAG3	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_1bec07e1-0186-4f45-bd8e-7d8a0f2547a9-2025-05-30T160000.000Z?page=1&size=25&search=	HGNC:939	dilated cardiomyopathy	MONDO:0005021	AD	Definitive	Yes	603883	Dilated cardiomyopathy	613881	Cardiovascular	AD	3,1	All P and LP		loss of function	любые	Нет		3	0																												
BAG3	https://search.clinicalgenome.org/kb/gene-validity/CGGCIEX:assertion_5466	HGNC:939	myofibrillar myopathy	MONDO:0018943	AD	Definitive	Yes	603883	Myofibrillar myopathy	612954	Cardiovascular	AD	3,1	All P and LP		?	в основном миссенс	Нет		?	?																												
BMPR1A	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_7004b10e-0eb6-4517-8deb-2d4b7264d2f8-2022-12-30T180000.000Z?page=1&size=25&search=	HGNC:1076	juvenile polyposis syndrome	MONDO:0017380	AD	Definitive	Yes	601299	Juvenile polyposis syndrome	174900	Cancer	AD	1	All P and LP		loss of function		Нет		3	0																												
BMPR1A	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_e810879d-f635-4851-b20e-86998b000fcc-2022-10-18T160000.000Z?page=1&size=25&search=	HGNC:1076	pulmonary arterial hypertension	MONDO:0015924	Other	Disputed	NA	601299										Нет																															
BRCA1		HGNC:1100	BRCA1-related cancer predisposition	MONDO:0700268	AD	Definitive	Yes	113705	Hereditary breast and ovarian cancer	604370	Cancer	AD	1	All P and LP	The pathogenic mechanism for both hereditary breast cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing breast cancer risk and biallelic variants causing Fanconi anemia. Therefore, P/LP variants that have been identified for either condition are reportable as SFs in the heterozygous or biallelic state.																																		
BRCA1		HGNC:1100	Fanconi anemia, complementation group S	MONDO:0054748	AR	Definitive	Yes?	113705			Cancer	AR	1	All P and LP	The pathogenic mechanism for both hereditary breast cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing breast cancer risk and biallelic variants causing Fanconi anemia. Therefore, P/LP variants that have been identified for either condition are reportable as SFs in the heterozygous or biallelic state.																																		
BRCA2		HGNC:1101	Fanconi anemia complementation group D1	MONDO:0011584	AR	Definitive	Yes?	600185			Cancer	AR	1	All P and LP	The pathogenic mechanism for both hereditary breast cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing breast cancer risk and biallelic variants causing Fanconi anemia. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.																																		
BRCA2		HGNC:1101	BRCA2-related cancer predisposition	MONDO:0700269	AD	Definitive	Yes	600185	Hereditary breast and ovarian cancer	612555	Cancer	AD	1	All P and LP	The pathogenic mechanism for both hereditary breast cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing breast cancer risk and biallelic variants causing Fanconi anemia. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.																																		
BTD		HGNC:1122	biotinidase deficiency	MONDO:0009665	AR	Definitive	Yes	609019	Biotinidase deficiency	253260	Metabolic	AR	3	P and LP (2 variants)	BTD is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).																																		
BTD		HGNC:1122	Leigh syndrome	MONDO:0009723	AR	Moderate	NA	609019																																									
CACNA1S		HGNC:1397	malignant hyperthermia, susceptibility to, 5	MONDO:0011163	AD	Moderate	Yes	114208	Malignant hyperthermia	601887	Other	AD	1	All P and LP																																			
CALM1		HGNC:1442	long QT syndrome	MONDO:0002442	AD	Definitive	Yes	114180	Long-QT syndrome type 14	616247	Cardiovascular	AD	3,2	All P and LP																																			
CALM1		HGNC:1442	catecholaminergic polymorphic ventricular tachycardia	MONDO:0017990	AD	Moderate	Yes	114180	Catecholaminergic polymorphic ventricular tachycardia	614916	Cardiovascular	AD	3,2	All P and LP																																			
CALM2		HGNC:1445	long QT syndrome	MONDO:0002442	AD	Definitive	Yes	114182	Long-QT syndrome type 15	616249	Cardiovascular	AD	3,2	All P and LP																																			
CALM2		HGNC:1445	catecholaminergic polymorphic ventricular tachycardia	MONDO:0017990	AD	Moderate	Yes	114182	Catecholaminergic polymorphic ventricular tachycardia	616249	Cardiovascular	AD	3,2	All P and LP																																			
CALM3		HGNC:1449	long QT syndrome	MONDO:0002442	AD	Definitive	Yes	114183	Long-QT syndrome type 16	618782	Cardiovascular	AD	3,2	All P and LP																																			
CALM3		HGNC:1449	catecholaminergic polymorphic ventricular tachycardia	MONDO:0017990	AD	Moderate	Yes	114183	Catecholaminergic polymorphic ventricular tachycardia	618782	Cardiovascular	AD	3,2	All P and LP																																			
CASQ2		HGNC:1513	catecholaminergic polymorphic ventricular tachycardia	MONDO:0017990	AR	Definitive	Yes	114251	Catecholaminergic polymorphic ventricular tachycardia	611938	Cardiovascular	AR	3	P and LP (2 variants)	It is recommended that only P/LP variants associated to autosomal recessive CPVT be returned as SFs as the data supporting dominant inheritance of certain variants is not strong enough to support return as SFs. Also, CASQ2 is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).																																		
CASQ2		HGNC:1513	hypertrophic cardiomyopathy	MONDO:0005045	AD	Disputed	NA	114251																																									
CASQ2		HGNC:1513	catecholaminergic polymorphic ventricular tachycardia	MONDO:0017990	AD	Moderate	No	114251																																									
COL3A1		HGNC:2201	Ehlers-Danlos syndrome, vascular type	MONDO:0017314	AD	Definitive	Yes	120180	Ehlers-Danlos syndrome, vascular type	130050	Cardiovascular	AD	1	All P and LP																																			
CYP27A1		HGNC:2605	cerebrotendinous xanthomatosis	MONDO:0008948	AR	Definitive	Yes	213700	Cerebrotendinous xanthomatosis	213700	Metabolic	AR	3,3	P and LP (2 variants)	CYP27A1 is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).																																		
DES		HGNC:2770	dilated cardiomyopathy	MONDO:0005021	AD	Definitive	Yes	125660	Dliated cardiomyopathy	604765	Cardiovascular	AD	3,1	All P and LP																																			
DES		HGNC:2770	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	Moderate	Yes	125660	Myofibrillar myopathy	601419	Cardiovascular	AD	3,1	All P and LP																																			
DSC2		HGNC:3036	familial isolated arrhythmogenic right ventricular dysplasia	MONDO:0016342	AD	Definitive	Yes	125645	Arrhythmogenic right ventricular cardiomyopathy	610476	Cardiovascular	AD	1	All P and LP																																			
DSG2		HGNC:3049	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	Definitive	Yes	125671	Arrhythmogenic right ventricular cardiomyopathy	610193	Cardiovascular	AD	1	All P and LP																																			
DSG2		HGNC:3049	dilated cardiomyopathy	MONDO:0005021	AD	Limited	NA	125671																																									
DSP		HGNC:3052	arrhythmogenic cardiomyopathy with wooly hair and keratoderma	MONDO:0011581	AD	Definitive	Yes	125647	Arrhythmogenic right ventricular cardiomyopathy	607450	Cardiovascular	AD	1	All P and LP																																			
DSP		HGNC:3052	hypertrophic cardiomyopathy	MONDO:0005045	AD	Disputed	NA	125647	Dilated cardiomyopathy	615821	Cardiovascular	AD	1	All P and LP																																			
ENG	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_d4d13b4a-f97b-45d0-9b82-07bcb6685a0a-2022-12-05T170000.000Z?page=1&size=25&search=	HGNC:3349	telangiectasia, hereditary hemorrhagic, type 1	MONDO:0008535	AD	Definitive	Yes	131195	Hereditary hemorrhagic telangiectasia	187300	Other	AD	3	All P and LP		haploinsufficiency and dominant negative	разные	Есть	https://cspec.genome.network/cspec/ui/svi/doc/GN136	3	0																												
ENG	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_08c5b377-a2a1-44ac-9b7e-dc2141ee7a04-2022-12-30T180000.000Z?page=1&size=25&search=	HGNC:3349	juvenile polyposis syndrome	MONDO:0017380	AD	Limited	NA	131195																																									
FBN1		HGNC:3603	Marfan syndrome	MONDO:0007947	AD	Definitive	Yes	134797	Marfan syndrome	154700	Cardiovascular	AD	1	All P and LP																																			
FBN1		HGNC:3603	familial thoracic aortic aneurysm and aortic dissection	MONDO:0019625	AD	Definitive	Yes?	134797																																									
FBN1		HGNC:3603	Shprintzen-Goldberg syndrome	MONDO:0008426	AD	Disputed	NA	134797																																									
FLNC		HGNC:3756	myofibrillar myopathy	MONDO:0018943	AD	Definitive	Yes	102565	Myofibrillar myopathy	609524	Cardiovascular	AD	3	All P and LP																																			
FLNC		HGNC:3756	dilated cardiomyopathy	MONDO:0005021	AD	Definitive	Yes	102565	Dilated cardiomyopathy	n/a	Cardiovascular	AD	3	All P and LP																																			
FLNC							Yes	102565	Hypertrophic cardiomyopathy	617047	Cardiovascular	AD	3	All P and LP			разобраться что тут творится																																
GAA		HGNC:4065	glycogen storage disease II	MONDO:0009290	AR	Definitive	Yes	606800	Pompe disease	232300	Metabolic	AR	3	P and LP (2 variants)	GAA is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).																																		
GLA		HGNC:4296	Fabry disease	MONDO:0010526	XL	Definitive	Yes	300644	Fabry disease	301500	Cardiovascular Metabolic	XL	1	All hemi, het, homozygous P and LP	Heterozygous and homozygous P/LP variants in females as well as hemizygous in males are reportable.																																		
HFE		HGNC:4886	hereditary hemochromatosis	MONDO:0006507	AR	Definitive	Yes	613609	Hereditary hemochromatosis (c.845G>A; p.C282Y homozygotes only)	235200	Other	AR	3	p.C282Y homozygotes only	Homozygous p.Cys282Tyr is the only reportable SF result.		p.C282Y homozygotes only																																
HNF1A		HGNC:11621	monogenic diabetes	MONDO:0015967	AD	Definitive	Yes	142410	Maturity-Onset of Diabetes of the Young	600496	Other	AD	3	All P and LP																																			
KCNH2		HGNC:6251	long QT syndrome	MONDO:0002442	AD	Definitive	Yes	152427	Long-QT syndrome type 2	613688	Cardiovascular	AD	1	All P and LP			описаны почти исключительно лоф варианты, очень редко миссенс																																
KCNH2		HGNC:6251	short QT syndrome	MONDO:0000453	AD	Definitive	Yes?	152427																																									
KCNH2		HGNC:6251	Brugada syndrome	MONDO:0015263	AD	Disputed	NA	152427																																									
KCNQ1		HGNC:6294	Jervell and Lange-Nielsen syndrome	MONDO:0002441	AR	Definitive	Yes?	607542																																									
KCNQ1		HGNC:6294	long QT syndrome	MONDO:0002442	AD	Definitive	Yes	607542	Long-QT syndrome type 1	192500	Cardiovascular	AD	1	All P and LP	Autosomal dominant longQT is due to pathogenic variants in KCNQ1, some of which act through a loss-of-function mechanism and others through a dominant negative gain-of-function mechanism. In contrast, autosomal recessive Jervell and Lange Nielson syndrome is due to pathogenic biallelic loss-of-function variants. P/LP variants implicated in either LQT or JLNS are reportable as SFs.																																		
KCNQ1		HGNC:6294	hypertrophic cardiomyopathy	MONDO:0005045	AD	Disputed	NA	607542																																									
KCNQ1		HGNC:6294	short QT syndrome	MONDO:0000453	AD	Strong	Yes?	607542																																									
LDLR		HGNC:6547	hypercholesterolemia, familial, 1	MONDO:0007750	SD	Definitive	Yes	606945	Familial hypercholesterolemia	143890	Cardiovascular	AD	1	All P and LP																																			
LMNA		HGNC:6636	dilated cardiomyopathy	MONDO:0005021	AD	Definitive	Yes	150330	Dilated cardiomyopathy	115200	Cardiovascular	AD	1	All P and LP	P/LP LMNA variants that have any case level phenotype evidence of association with cardiac disease (eg, DCM, arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, and/or arrhythmia) should be reported as SFs, whereas previously reported P/LP missense variants never associated with cardiac disease should not be reported. Also, for novel pLOF variants that reach LP without case observations, these variants should be reported given the general association of pLOF LMNA variants with cardiac disease and the evidence summary should include mention of the spectrum of phenotypes that may be observed with LMNA pLOF variation.																																		
LMNA		HGNC:6636	lipodystrophy	MONDO:0006573	SD	Definitive	Pending	150330																																									
LMNA		HGNC:6636	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	Limited	NA	150330																																									
MAX		HGNC:6913	hereditary pheochromocytoma-paraganglioma	MONDO:0017366	AD	Definitive	Yes	154950	Hereditary paraganglioma-pheochromocytoma syndrome	171300	Cancer	AD	3	All P and LP																																			
MEN1		HGNC:7010	multiple endocrine neoplasia type 1	MONDO:0007540	AD	Definitive	Yes	613733	Multiple endocrine neoplasia type 1	131100	Cancer	AD	1	All P and LP																																			
MLH1		HGNC:7127	Lynch syndrome	MONDO:0005835	AD	Definitive	Yes	120436	Lynch syndrome	609310	Cancer	AD	1	All P and LP	The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.																																		
MLH1		HGNC:7127	mismatch repair cancer syndrome 1	MONDO:0010159	AR	Definitive	Yes?	120436																																									
MLH1		HGNC:7127	hereditary breast carcinoma	MONDO:0016419	AD	Refuted	NA	120436																																									
MSH2		HGNC:7325	Lynch syndrome	MONDO:0005835	AD	Definitive	Yes	609309	Lynch syndrome	120435	Cancer	AD	1	All P and LP	The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.																																		
MSH2		HGNC:7325	mismatch repair cancer syndrome 1	MONDO:0010159	AR	Definitive	Yes?	609309																																									
MSH2		HGNC:7325	hereditary breast carcinoma	MONDO:0016419	AD	Refuted	NA	609309																																									
MSH6		HGNC:7329	mismatch repair cancer syndrome 1	MONDO:0010159	AR	Definitive	Yes?	600678																																									
MSH6		HGNC:7329	Lynch syndrome	MONDO:0005835	AD	Definitive	Yes	600678	Lynch syndrome	614350	Cancer	AD	1	All P and LP	The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.																																		
MSH6		HGNC:7329	hereditary breast carcinoma	MONDO:0016419	AD	Disputed	NA	600678																																									
MUTYH		HGNC:7527	familial adenomatous polyposis 2	MONDO:0012041	AR	Definitive	Yes	604933	MUTYH-associated polyposis	608456	Cancer	AR	1	P and LP (2 variants)	MUTYH is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return as SFs if the variants do not have prior evidence of existing in cis (on the same copy of the gene).																																		
MUTYH		HGNC:7527	familial ovarian cancer	MONDO:0016248	AR	Disputed	NA	604933																																									
MUTYH		HGNC:7527	familial ovarian cancer	MONDO:0016248	AD	Disputed	NA	604933																																									
MUTYH		HGNC:7527	hereditary breast carcinoma	MONDO:0016419	AR	Disputed	NA	604933																																									
MUTYH		HGNC:7527	colorectal cancer	MONDO:0005575	AD	Disputed	NA	604933																																									
MUTYH		HGNC:7527	hereditary breast carcinoma	MONDO:0016419	AD	Refuted	NA	604933																																									
MYBPC3		HGNC:7551	hypertrophic cardiomyopathy	MONDO:0005045	AD	Definitive	Yes	600958	Hypertrophic cardiomyopathy	115197	Cardiovascular	AD	1	All P and LP																																			
MYBPC3		HGNC:7551	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	Limited	NA	600958																																									
MYBPC3		HGNC:7551	congenital heart disease	MONDO:0005453	AD	Limited	NA	600958																																									
MYBPC3		HGNC:7551	dilated cardiomyopathy	MONDO:0005021	AD	Limited	NA	600958																																									
MYH11		HGNC:7569	familial thoracic aortic aneurysm and aortic dissection	MONDO:0019625	AD	Definitive	Yes	160745	Familial thoracic aortic aneurysm	132900	Cardiovascular	AD	1	All P and LP																																			
MYH11		HGNC:7569	congenital heart disease	MONDO:0005453	AD	Limited	NA	160745																																									
MYH7		HGNC:7577	hypertrophic cardiomyopathy	MONDO:0005045	AD	Definitive	Yes	160760	Hypertrophic cardiomyopathy	192600	Cardiovascular	AD	1	All P and LP	Loss-of-function variants in MYH7 are NOT known to be associated with disease in the heterozygous state. Distinct pathogenic variants in MYH7 have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy and MYH7-related skeletal myopathy through different molecular mechanisms. Most HCM related variants are located in the head domain potentially affecting actin binding sites. DCM has been associated with variants that produce an abnormal protein with reduced function. Variants associated to skeletal myopathy are usually located in the rod domain and may be due to a dominant negative mechanism. Note: This text was summarized from ClinGen’s gene-disease validity evidence summaries for MYH7. https://search.clinicalgenome.org/kb/genes/HGNC:7577 The ACMG Secondary Findings working group recommends that P/LP variants associated with cardiomyopathy, but not skeletal myopathy be returned as SFs.		не LOF																																
MYH7		HGNC:7577	dilated cardiomyopathy	MONDO:0005021	AD	Definitive	Yes	160760	Dilated cardiomyopathy	613426	Cardiovascular	AD	1	All P and LP	Loss-of-function variants in MYH7 are NOT known to be associated with disease in the heterozygous state. Distinct pathogenic variants in MYH7 have been associated with hypertrophic cardiomyopathy, dilated cardiomyopathy and MYH7-related skeletal myopathy through different molecular mechanisms. Most HCM related variants are located in the head domain potentially affecting actin binding sites. DCM has been associated with variants that produce an abnormal protein with reduced function. Variants associated to skeletal myopathy are usually located in the rod domain and may be due to a dominant negative mechanism. Note: This text was summarized from ClinGen’s gene-disease validity evidence summaries for MYH7. https://search.clinicalgenome.org/kb/genes/HGNC:7577 The ACMG Secondary Findings working group recommends that P/LP variants associated with cardiomyopathy, but not skeletal myopathy be returned as SFs.		не LOF																																
MYH7		HGNC:7577	MYH7-related skeletal myopathy	MONDO:0008050	AD	Definitive	No	160760																																									
MYH7		HGNC:7577	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	Limited	NA	160760																																									
MYH7		HGNC:7577	congenital heart disease	MONDO:0005453	AD	Limited	NA	160760																																									
MYL2		HGNC:7583	hypertrophic cardiomyopathy	MONDO:0005045	AD	Definitive	Yes	160781	Hypertrophic cardiomyopathy	608758	Cardiovascular	AD	1	All P and LP																																			
MYL2		HGNC:7583	hypertrophic cardiomyopathy 10	MONDO:0012112	AD	Definitive	Yes?	160781																																									
MYL2		HGNC:7583	dilated cardiomyopathy	MONDO:0005021	AD	Limited	NA	160781																																									
MYL2		HGNC:7583	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	No Known Disease Relationship	NA	160781																																									
MYL3		HGNC:7584	hypertrophic cardiomyopathy	MONDO:0005045	AD	Definitive	Yes	160790	Hypertrophic cardiomyopathy	608751	Cardiovascular	AD	1	All P and LP																																			
MYL3		HGNC:7584	dilated cardiomyopathy	MONDO:0005021	AD	Disputed	NA	160790																																									
MYL3		HGNC:7584	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	Limited	NA	160790																																									
NF2		HGNC:7773	NF2-related schwannomatosis	MONDO:0007039	AD	Definitive	Yes	607379	NF2-related schwannomatosis	101000	Cancer	AD	1	All P and LP																																			
OTC		HGNC:8512	ornithine carbamoyltransferase deficiency	MONDO:0010703	XL	Definitive	Yes	300461	Ornithine transcarbamylase deficiency	311250	Metabolic	XL	2	All hemi, het, homozygous P and LP	Heterozygous and homozygous P/LP variants in females as well as hemizygous in males are reportable.																																		
PALB2		HGNC:26144	Fanconi anemia complementation group N	MONDO:0012565	AR	Definitive	Yes?	610355					3	All P and LP		loss of function	только лофы	Есть	https://cspec.genome.network/cspec/ui/svi/doc/GN077	3	0																												
PALB2		HGNC:26144	PALB2-related cancer predisposition	MONDO:0700272	AD	Definitive	Yes	610355	Hereditary breast cancer	114480	Cancer	AD	3	All P and LP	The pathogenic mechanism for both hereditary cancer and Fanconi anemia is the same (loss-of-function), with single heterozygous variants causing hereditary cancer and biallelic variants causing Fanconi anemia. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.	loss of function	только лофы	Есть	https://cspec.genome.network/cspec/ui/svi/doc/GN077	3	0																												
PCSK9	https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_bf710ddc-c189-419f-ab70-25300b067db2-2018-11-14T170000.000Z?page=1&size=25&search=	HGNC:20001	hypercholesterolemia, autosomal dominant, 3	MONDO:0011369	AD	Definitive	Yes	607786	Familial hypercholesterolemia	603776	Cardiovascular	AD	1	All P and LP	The mechanism of pathogenicity for hypercholesterolemia is gain-of-function variants. LOF variants should not be reported as SFs as they are associated with low levels of LDL cholesterol.		GOF	Нет		40	0																												
PKP2		HGNC:9024	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	Definitive	Yes	602861	Arrhythmogenic right ventricular cardiomyopathy	609040	Cardiovascular	AD	1	All P and LP																																			
PKP2		HGNC:9024	catecholaminergic polymorphic ventricular tachycardia	MONDO:0017990	AD	Disputed	NA	602861																																									
PKP2		HGNC:9024	dilated cardiomyopathy	MONDO:0005021	AD	Disputed	NA	602861																																									
PKP2		HGNC:9024	Brugada syndrome 1	MONDO:0011001	AD	Disputed	NA	602861																																									
PLN		HGNC:9080	intrinsic cardiomyopathy	MONDO:0000591	AD	Definitive	Yes	172405	Dilated cardiomyopathy	609909	Cardiovascular	AD	3,3	All P and LP	The typical inheritance for PLN related cardiomyopathy is autosomal dominant, albeit autosomal recessive inheritance has been noted and appears to follow a dosage effect or semidominance, as loss of both alleles results in an earlier and more severe phenotypic presentation (PMID: 12639993). Missense, pLOF and promoter variants have all been reported as pathogenic. Given that PLN only has one exon, most variants, including pLOFs, result in a protein product. There is no observed difference in molecular mechanism(s) underlying the various forms of cardiomyopathy including dilated, hypertrophic and arrhythmogenic right ventricular cardiomyopathy. Both interfamilial and intrafamilial variability are observed between PLN variants (PMID: 12639993, 22820313). Therefore, all of the disease entities have been lumped into one disease entity, Intrinsic cardiomyopathy. There is a relatively common Dutch founder pathogenic variant NM_002667.5 c.37AGA[1] (p.Arg14del) that may be present in up to 10-15% of patients with DCM or ARVC in the Netherlands. Note, this information was summarized from ClinGen's gene-disease validity evidence summaries for PLN: https://search.clinicalgenome.org/kb/genes/HGNC:9080																																		
PLN		HGNC:9080	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	Moderate	Yes?	172405																																									
PMS2		HGNC:9122	Lynch syndrome	MONDO:0005835	AD	Definitive	Yes	600259	Lynch syndrome	614337	Cancer	AD	1	All P and LP	The pathogenic mechanism for both Lynch syndrome and mismatch repair cancer syndrome is the same (loss-of-function), with single heterozygous variants causing Lynch and biallelic variants causing mismatch repair cancer syndrome. Therefore, P/LP variants identified for either condition are reportable as SFs in the heterozygous or biallelic state.																																		
PMS2		HGNC:9122	mismatch repair cancer syndrome 1	MONDO:0010159	AR	Definitive	Yes?	600259																																									
PMS2		HGNC:9122	hereditary breast carcinoma	MONDO:0016419	AD	Disputed	NA	600259																																									
PRKAG2		HGNC:9386	PRKAG2-related cardiomyopathy	MONDO:0800484	AD	Definitive	Yes	602743	Hypertrophic cardiomyopathy	600858	Cardiovascular Metabolic	AD	1	All P and LP																																			
PTEN		HGNC:9588	PTEN hamartoma tumor syndrome	MONDO:0017623	AD	Definitive	Yes	601728	PTEN hamartoma tumor syndrome	158350	Cancer	AD	1	All P and LP																																			
RB1		HGNC:9884	retinoblastoma	MONDO:0008380	AD	Definitive	Yes	614041	Retinoblastoma	180200	Cancer	AD	1	All P and LP																																			
RBM20		HGNC:27424	dilated cardiomyopathy	MONDO:0005021	AD	Definitive	Yes	613171	Dliated cardiomyopathy	613172	Cardiovascular	AD	3,1	All P and LP																																			
RBM20		HGNC:27424	hypertrophic cardiomyopathy	MONDO:0005045	AD	Limited	NA	613171																																									
RET		HGNC:9967	multiple endocrine neoplasia type 2B	MONDO:0008082	AD	Definitive	Yes	164761	Multiple endocrine neoplasia type 2B	162300	Cancer	AD	1	All P and LP	The mechanism of pathogenicity for multiple endocrine neoplasia is gain-of-function. LOF variants should not be reported as SFs.																																		
RET		HGNC:9967	multiple endocrine neoplasia type 2A	MONDO:0008234	AD	Definitive	Yes	164761	Multiple endocrine neoplasia type 2A	171400	Cancer	AD	1	All P and LP	The mechanism of pathogenicity for multiple endocrine neoplasia is gain-of-function. LOF variants should not be reported as SFs.																																		
RET							Yes?	164761	Familial medullary thyroid cancer	155240	Cancer	AD	1	All P and LP	The mechanism of pathogenicity for multiple endocrine neoplasia is gain-of-function. LOF variants should not be reported as SFs.																																		
RPE65		HGNC:10294	RPE65-related recessive retinopathy	MONDO:0100368	AR	Definitive	Yes	180069	RPE65-related retinopathy	204100,  613794	Other	AR	3	P and LP (2 variants)	Only variants associated with autosomal recessive disease are suggested for SF return by the ACMG SF working group. There is currently only one valid dominant pathogenic variant and individuals with this variant are not eligible for gene therapy and therefore this variant is not recommended for return as a SF at this time. Also, RPE65 is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return if the variants do not have prior evidence of existing in cis (on the same copy of the gene).																																		
RPE65		HGNC:10294	RPE65-related dominant retinopathy	MONDO:0100452	AD	Strong	No	180069																																									
RYR1		HGNC:10483	malignant hyperthermia, susceptibility to, 1	MONDO:0007783	AD	Definitive	Yes	180901	Malignant hyperthermia	145600	Other	AD	1	All P and LP	P/LP variants in RYR1 can be associated with either malignant hyperthermia or a neuromuscular phenotype. Only P/LP variants associated with malignant hyperthermia should be reported as SFs.																																		
RYR1		HGNC:10483	RYR1-related myopathy	MONDO:0100150	AR	Definitive	No	180901																																									
RYR1		HGNC:10483	RYR1-related myopathy	MONDO:0100150	AD	Definitive	No	180901																																									
RYR2		HGNC:10484	catecholaminergic polymorphic ventricular tachycardia	MONDO:0017990	AD	Definitive	Yes	180902	Catecholaminergic polymorphic ventricular tachycardia	604772	Cardiovascular	AD	1	All P and LP																																			
RYR2		HGNC:10484	hypertrophic cardiomyopathy	MONDO:0005045	AD	Limited	NA	180902																																									
RYR2		HGNC:10484	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	Refuted	NA	180902																																									
SCN5A		HGNC:10593	dilated cardiomyopathy	MONDO:0005021	AD	Definitive	Yes	600163	Dilated cardiomyopathy	601154	Cardiovascular	AD	1	All P and LP																																			
SCN5A		HGNC:10593	familial long QT syndrome	MONDO:0019171	AD	Definitive	Yes	600163	Long QT syndrome type 3	603830	Cardiovascular	AD	1	All P and LP																																			
SCN5A		HGNC:10593	Brugada syndrome	MONDO:0015263	AD	Definitive	Yes	600163	Brugada syndrome	601144	Cardiovascular	AD	1	All P and LP																																			
SCN5A		HGNC:10593	short QT syndrome	MONDO:0000453	AD	Disputed	NA	600163																																									
SCN5A		HGNC:10593	catecholaminergic polymorphic ventricular tachycardia	MONDO:0017990	AD	Disputed	NA	600163																																									
SCN5A		HGNC:10593	congenital heart disease	MONDO:0005453	AD	Disputed	NA	600163																																									
SCN5A		HGNC:10593	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	Limited	NA	600163																																									
SDHAF2		HGNC:26034	hereditary pheochromocytoma-paraganglioma	MONDO:0017366	AD	Definitive	Yes	613019	Hereditary paraganglioma-pheochromocytoma syndrome	601650	Cancer	AD	1	All P and LP																																			
SDHB		HGNC:10681	mitochondrial disease	MONDO:0044970	AR	Definitive	No	185470																																									
SDHB		HGNC:10681	hereditary pheochromocytoma-paraganglioma	MONDO:0017366	AD	Definitive	Yes	185470	Hereditary paraganglioma-pheochromocytoma syndrome	115310,  171300	Cancer	AD	1	All P and LP																																			
SDHC		HGNC:10682	hereditary pheochromocytoma-paraganglioma	MONDO:0017366	AD	Definitive	Yes	602413	Hereditary paraganglioma-pheochromocytoma syndrome	605373	Cancer	AD	1	All P and LP																																			
SDHC		HGNC:10682	mitochondrial disease	MONDO:0044970	Other	No Known Disease Relationship	NA	602413																																									
SDHD		HGNC:10683	hereditary pheochromocytoma-paraganglioma	MONDO:0017366	AD	Definitive	Yes	602690	Hereditary paraganglioma-pheochromocytoma syndrome	168000,  171300	Cancer	AD	1	All P and LP																																			
SDHD		HGNC:10683	mitochondrial disease	MONDO:0044970	AR	Limited	NA	602690																																									
SMAD3		HGNC:6769	aneurysm-osteoarthritis syndrome	MONDO:0013426	AD	Definitive	Yes	603109	Loeys-Dietz syndrome	613795	Cardiovascular	AD	1	All P and LP																																			
SMAD3		HGNC:6769	familial thoracic aortic aneurysm and aortic dissection	MONDO:0019625	AD	Definitive	Yes?	603109																																									
SMAD4		HGNC:6770	Myhre syndrome	MONDO:0007688	AD	Definitive	No	600993																																									
SMAD4		HGNC:6770	juvenile polyposis	MONDO:0008278	AD	Definitive	Yes	600993	Juvenile polyposis syndrome	174900	Cancer	AD	1	All P and LP	P/LP variants in SMAD4 are linked to juvenile polyposis with hereditary hemorrhagic telangiectasia (JP/HHT) syndrome, juvenile intestinal polyposis syndrome (JPS), and Myhre syndrome. P/LP variants causal for JP/HHT and JPS are due to heterozygous loss-of-function variants and are reportable as SF results. Myhre syndrome, a multi-system disorder involving intellectual disability, is caused by one of four SMAD4 missense variants [c.1498A>G (p.Ile500Val); c.1499T>C (p.Ile500Thr); c.1500A>G (p.Ile500Met), and c.1486C>T (p.Arg496Cys)] and is not on the list of reportable diseases. Variants for Myhre syndrome should not be returned.																																		
SMAD4		HGNC:6770	hereditary hemorrhagic telangiectasia syndrome	MONDO:0008278	AD	Definitive	Yes	600993	Hereditary hemorrhagic telangiectasia	175050	Other	AD	1	All P and LP	P/LP variants in SMAD4 are linked to juvenile polyposis with hereditary hemorrhagic telangiectasia (JP/HHT) syndrome, juvenile intestinal polyposis syndrome (JPS), and Myhre syndrome. P/LP variants causal for JP/HHT and JPS are due to heterozygous loss-of-function variants and are reportable as SF results. Myhre syndrome, a multi-system disorder involving intellectual disability, is caused by one of four SMAD4 missense variants [c.1498A>G (p.Ile500Val); c.1499T>C (p.Ile500Thr); c.1500A>G (p.Ile500Met), and c.1486C>T (p.Arg496Cys)] and is not on the list of reportable diseases. Variants for Myhre syndrome should not be returned.																																		
SMAD4		HGNC:6770	pulmonary arterial hypertension	MONDO:0015924	AD	Disputed	NA	600993																																									
STK11		HGNC:11389	Peutz-Jeghers syndrome	MONDO:0008280	AD	Definitive	Yes	602216	Peutz-Jeghers syndrome	175200	Cancer	AD	1	All P and LP																																			
STK11		HGNC:11389	familial ovarian cancer	MONDO:0016248	AD	No Known Disease Relationship	NA	602216																																									
TGFBR1		HGNC:11772	multiple self-healing squamous epithelioma	MONDO:0007566	AD	Definitive	No	190181																																									
TGFBR1		HGNC:11772	Loeys-Dietz syndrome	MONDO:0018954	AD	Definitive	Yes	190181	Loeys-Dietz syndrome	609192	Cardiovascular	AD	1	All P and LP	P/LP missense variants in the intracellular kinase domain of TGFBR1 are known to cause Loeys-Dietz syndrome with unclear molecular mechanism which could include gain-of-function and dominant negative. These variants are returnable as SFs. In contrast, truncating variants or missense variants in the receptor domain of TGFBR1 cause multiple self-healing squamous epithelioma (MSSE; OMIM 132800) with loss-of-function mechanism and are not returnable as SFs.																																		
TGFBR1		HGNC:11772	familial thoracic aortic aneurysm and aortic dissection	MONDO:0019625	AD	Definitive	Yes?	190181																																									
TGFBR2		HGNC:11773	Loeys-Dietz syndrome 2	MONDO:0012427	AD	Definitive	Yes	190182	Loeys-Dietz syndrome	610168	Cardiovascular	AD	1	All P and LP																																			
TGFBR2		HGNC:11773	familial thoracic aortic aneurysm and aortic dissection	MONDO:0019625	AD	Definitive	Yes?	190182																																									
TMEM127		HGNC:26038	hereditary pheochromocytoma-paraganglioma	MONDO:0017366	AD	Definitive	Yes	613403	Hereditary paraganglioma-pheochromocytoma syndrome	171300	Cancer	AD	3	All P and LP																																			
TMEM43		HGNC:28472	arrhythmogenic right ventricular dysplasia 5	MONDO:0011459	AD	Definitive	Yes	612048	Arrhythmogenic right ventricular cardiomyopathy	604400	Cardiovascular	AD	1	All P and LP																																			
TNNC1		HGNC:11943	hypertrophic cardiomyopathy	MONDO:0005045	AD	Definitive	Yes?	191040																																									
TNNC1		HGNC:11943	dilated cardiomyopathy	MONDO:0005021	AD	Definitive	Yes	191040	Dilated cardiomyopathy	611879	Cardiovascular	AD	3,1	All P and LP																																			
TNNC1		HGNC:11943	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	No Known Disease Relationship	NA	191040																																									
TNNI3		HGNC:11947	hypertrophic cardiomyopathy	MONDO:0005045	AD	Definitive	Yes	191044	Hypertrophic cardiomyopathy	613690	Cardiovascular	AD	1	All P and LP																																			
TNNI3		HGNC:11947	dilated cardiomyopathy	MONDO:0005021	AD	Moderate	Yes?	191044																																									
TNNI3		HGNC:11947	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	No Known Disease Relationship	NA	191044																																									
TNNT2		HGNC:11949	dilated cardiomyopathy	MONDO:0005021	AD	Definitive	Yes	191045	Dilated cardiomyopathy	601494	Cardiovascular	AD	1	All P and LP																																			
TNNT2		HGNC:11949	hypertrophic cardiomyopathy	MONDO:0005045	AD	Moderate	Yes	191045	Hypertrophic cardiomyopathy	115195	Cardiovascular	AD	1	All P and LP																																			
TNNT2		HGNC:11949	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	No Known Disease Relationship	NA	191045																																									
TP53		HGNC:11998	Li-Fraumeni syndrome	MONDO:0018875	AD	Definitive	Yes	191170	Li-Fraumeni syndrome	151623	Cancer	AD	1	All P and LP																																			
TPM1		HGNC:12010	hypertrophic cardiomyopathy	MONDO:0005045	AD	Definitive	Yes	191010	Hypertrophic cardiomyopathy	115196	Cardiovascular	AD	1	All P and LP																																			
TPM1		HGNC:12010	dilated cardiomyopathy	MONDO:0005021	AD	Moderate	Yes?	191010																																									
TPM1		HGNC:12010	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	No Known Disease Relationship	NA	191010																																									
TRDN		HGNC:12261	catecholaminergic polymorphic ventricular tachycardia	MONDO:0017990	AR	Definitive	Yes	603283	Catecholaminergic polymorphic ventricular tachycardia	615441	Cardiovascular	AR	3	All P and LP	The MANE Select transcript, NM_006073.4, which has 41 exons, is not the relevant transcript for cardiac disease reporting. Variants should only be reported in exons 1-8 of NM_001256021.1, the predominant transcript in cardiac tissue. Also, TRDN is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return if the variants do not have prior evidence of existing in cis (on the same copy of the gene).																																		
TRDN		HGNC:12261	long QT syndrome	MONDO:0002442	AR	Strong	Yes	603283	Long QT syndrome	n/a	Cardiovascular	AR	3	All P and LP	The MANE Select transcript, NM_006073.4, which has 41 exons, is not the relevant transcript for cardiac disease reporting. Variants should only be reported in exons 1-8 of NM_001256021.1, the predominant transcript in cardiac tissue. Also, TRDN is only reportable if there are biallelic P/LP variants. If phase is unknown for two heterozygous P/LP variants, the variants are acceptable for return if the variants do not have prior evidence of existing in cis (on the same copy of the gene).																																		
TSC1		HGNC:12362	tuberous sclerosis	MONDO:0001734	AD	Definitive	Yes	605284	Tuberous sclerosis complex	191100	Cancer	AD	1	All P and LP																																			
TSC2		HGNC:12363	tuberous sclerosis	MONDO:0001734	AD	Definitive	Yes	191092	Tuberous sclerosis complex	613254	Cancer	AD	1	All P and LP																																			
TTN		HGNC:12403	dilated cardiomyopathy	MONDO:0005021	AD	Definitive	Yes	188840	Dilated cardiomyopathy (truncating variants only)	604145	Cardiovascular	AD	3	P and LP (truncating variants only)	Frameshift, nonsense, and splice-impacting variants in TTN exons with high PSI (see references PMCID: PMC4560092; PMC5201198; http://cardiodb.org/titin) should be evaluated for pathogenicity and returned as SFs if classified as P/LP for dilated cardiomyopathy. Distinct pathogenic variants are associated with different forms of both AD and AR muscle disease (see ClinGen GCEP reports) and are not recommended for return as SFs.																																		
TTN		HGNC:12403	TTN-related myopathy	MONDO:0100175	AR	Definitive	No	188840																																									
TTN		HGNC:12403	arrhythmogenic right ventricular cardiomyopathy	MONDO:0016587	AD	Limited	NA	188840																																									
TTN		HGNC:12403	hypertrophic cardiomyopathy	MONDO:0005045	AD	Limited	NA	188840																																									
TTN		HGNC:12403	myopathy, myofibrillar, 9, with early respiratory failure	MONDO:0011362	AD	Moderate	No	188840																																									
TTN		HGNC:12403	tibial muscular dystrophy	MONDO:0010870	AD	Moderate	No	188840																																									
TTR		HGNC:12405	hereditary ATTR amyloidosis	MONDO:0017132	AD	Definitive	Yes	176300	Hereditary transthyretin-related amyloidosis	105210	Other	AD	3,1	All P and LP																																			
VHL		HGNC:12687	von Hippel-Lindau disease	MONDO:0008667	AD	Definitive	Yes	608537	Von Hippel-Lindau syndrome	193300	Cancer	AD	1	All P and LP																																			
WT1		HGNC:12796	Wilms tumor 1	MONDO:0008679	AD	Definitive	Yes	607102	WT1-related Wilms tumor	194070	Cancer	AD	1	All P and LP																																			
WT1		HGNC:12796	Denys-Drash syndrome	MONDO:0008682	AD	Definitive	Pending	607102																																									